Nuvectis Pharma, Inc. — Form 10-Q
Filed November 4, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Nuvectis Pharma and Haisco Pharmaceutical entered an exclusive license agreement dated June 22, 2026, for two drug programs: HSK42360 (BRaf kinase inhibitor) and HSK39297 (Factor B inhibitor). The agreement grants Nuvectis exclusive rights to develop and commercialize these compounds in its territory; Haisco retains rights in the Haisco Territory. The deal is contingent on Nuvectis completing financing by June 30, 2026 and a subsequent financing within 6 months. No specific upfront payment, milestone, or royalty amounts are disclosed in the redacted filing; financial terms are identified as [***].
Why this rating
Standard biotech licensing with financing condition; material deal type but dollar amounts redacted and company ~$100M market cap mean deal scale unclear. Boilerplate governance and IP terms. No disclosed financial commitment creates ambiguity on materiality.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.